Nektar Therapeutics buy DomRuinart
Summary
This prediction ended on 25.04.19 with a price of €28.08. The prediction for Nektar Therapeutics disappointed with a performance of -15.18%. DomRuinart has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Nektar Therapeutics | -4.788% | -4.788% | 134.268% | -89.378% |
| iShares Core DAX® | -0.268% | 5.471% | 14.271% | 19.027% |
| iShares Nasdaq 100 | 1.854% | 7.851% | 35.426% | 58.415% |
| iShares Nikkei 225® | 0.284% | 1.729% | 9.943% | 7.045% |
| iShares S&P 500 | 1.178% | 5.269% | 27.989% | 49.400% |
Comments by DomRuinart for this prediction
In the thread Nektar Therapeutics diskutieren
noch nicht abschreiben
Ich denke hier kann man langsam wieder Positionen aufbauen. Nektar hat weiterhin enormes Potential. Das Unternehmen wird noch beträchtliche Meilensteinzahlungen u.a. von Eli Lilly und Bristol-Meyers Squibb erhalten. Vor allem letztere haben bereits enorme Summen in NKTR-214 geschossen und sind mit Ihrem Bestseller Opdivo quasi auf den Erfolg von NKTR-214 angewiesen, wenn sie hier noch Wachstum generieren wollen. Da Nektar neben den Meilensteinzahlungen noch 65% der Verkaufserlöse einsacken kann, wenn Opdivo in Verbindung mit NKTR-214 eingesetzt wird sollte man den Laden noch längst nicht abschreiben:
Why You Shouldn't Count Out Nektar Therapeutics (NASDAQ:NKTR) Stock
Brittany Pennington
10-24-2018 3:34PM
October hasn't been the best month for Nektar Therapeutics (NASDAQ:NKTR) following a less-than-promising report on the efficacy of the company's lead immuno-oncology candidate NKTR-214's use alongside Bristol-Myers Squibb Co (NYSE:BMY)'s Opdivo in treating cancer patients. In fact, investors saw NKTR stock plummet a frightening 17.2% in one day alone. The company behind the report, Plainview LLC, acknowledged that it has a short position on NKTR-214. It is important to note there remains the potential for success in large, late-stage studies and Nektar Therapeutics (NASDAQ:NKTR) has had 10 abstracts accepted for presentation at the Society for Immunotherapy of Cancer meeting next month.
Nektar Therapeutics (NASDAQ:NKTR) Has More to Offer
According to the company's website, Nektar Therapeutics (NASDAQ:NKTR) has "a deep and diverse portfolio of investigational medicines in different stages of clinical development" and remains "focused on using new chemistry approaches to make better medicines to treat cancer, chronic pain and auto-immune disease." Nektar Therapeutics (NASDAQ:NKTR) also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies including Biogen Inc (NASDAQ:BIIB), Bristol-Myers Squibb Co (NYSE:BMY), Eli Lilly and Co (NYSE:LLY), Halozyme Therapeutics, Inc. (NASDAQ:HALO), and others.
Revenue was higher in the second quarter and first half of 2018 as compared to the same periods in 2017 primarily because of the recognition of $1.06 billion of license revenue from the Bristol-Myers Squibb collaboration agreement. Upon the collaboration agreement becoming effective on April 3, 2018, Bristol-Myers Squibb Co (NYSE:BMY) made a non-refundable upfront cash payment of $1.0 billion to Nektar Therapeutics (NASDAQ:NKTR).
It is easy to see why Bristol-Myers Squibb Co (NYSE:BY) isn't quite ready to back away from NKTR-214. A phase 3 study in advanced melanoma began in the third quarter, and phase 3 trials are also being planned in kidney cancer. The Hade Platform also holds a bullish stance for Nektar Therapeutics (NASDAQ:NKTR), as the stock maintains a very strong investment grade of 90 on our Top 100. With overall investment grades still lower, we suggest holding large sums of cash and being very selective when making investment decisions. According to NKTR stock’s current grade, it might very well be one of those selective opportunities.
Quelle: HadePlatform